Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

NCT06813365 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonsmall-cell Lung Cancer

Interventions

DRUG: DZD6008

Sponsor

Dizal Pharmaceuticals